Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when ...

Ethan Mollick’s idea of the ‘jagged frontier’ of AI 1 is one of the most useful ways of describing the problem with the ...

The race to harness and exploit generative AI (GenAI) in healthcare is at a feverish state, with agencies and pharmaceutical companies building platforms and creative departments plundering ...

In a deal worth $950m, GSK has agreed to acquire 35Pharma, a private, clinical-stage biopharmaceutical company based in Canada that specialises in the development of novel protein-based therapeutics.

Incyte Biosciences UK has received NICE approval for eligible NHS patients with non-segmental vitiligo to be reimbursed for Opzelura (ruxolitinib) cream 15mg/g. This comes after more than two years of ...

As of 1 January 2027, Novo Nordisk will lower the list price, or wholesale acquisition cost, to $675 for Wegovy (semaglutide) ...

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve ...

Proud to be ranked 3rd among the Top 10 UK-focused agencies, along with other categories, Grace Communications finds inspiration in being included in PMLive’s Top 40 Creative Healthcare Agencies 2025.

FlyPharma Conferences is delighted to announce that FlyPharma Copenhagen, in partnership with Copenhagen Airport (CPH), SAS Cargo and World Courier, will take place from 6 to 7 October 2026 at the ...

Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union ...

The board will support the CGT Catapult in identifying and removing barriers to the widespread adoption of advanced therapies ...

This month we have a special feature on GenAI and its impact on pharma – from intelligent content generation to optimising ...